Clinical Trials Browser

Phase 1/2 × Recruiting × Non-Muscle Invasive Bladder Neoplasms × Clear all

Non-Muscle Invasive Bladder Neoplasms

NCT05316155 2026-05-08

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

235 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-05-01

TroFuse-027

Phase 1/2 Recruiting

32 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07122414 2025-08-14

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

80 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04106115 2024-12-04

DURANCE

Phase 1/2 Recruiting

64 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05232136 2024-08-12

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

Phase 1/2 Recruiting

30 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

TroFuse-027

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

ADAPT-BLADDER

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

DURANCE

OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer